Printer Friendly

MEDIMMUNE REPORTS INCREASED PRODUCT SALES IN SECOND QUARTER

 GAITHERSBURG, Md., Aug. 6 /PRNewswire/ -- MedImmune, Inc. (NASDAQ: MEDI) today reported results for the second quarter ended June 30, 1993. Sales of MedImmune's first product, CytoGam(R), increased to $1.9 million from $1.2 million in the prior year period and $1.6 million in the first quarter. CytoGam(R) is a polyclonal antibody product used to prevent cytomegalovirus (CMV) disease in kidney transplant patients.
 "We are very pleased with the 19 percent increase in CytoGam sales over the first quarter," said Wayne T. Hockmeyer, Ph.D., chairman and chief executive officer. "We continue to be encouraged by the response of customers to the safety and efficacy of the product and to the marketing program we initiated through our own sales force in January 1993."
 For the second quarter ended June 30, 1993, MedImmune reported total revenues of $2.3 million and a net loss of $3.4 million, or $0.20 per share. Revenues and earnings for the prior year period of $4.1 million and $0.2 million, or $0.01 per share, reflected higher contract research revenue from Merck & Co., Inc. for a collaborative HIV research program.
 Operating expenses for the 1993 second quarter were $6.1 million, compared to $4.6 million in the 1992 quarter. This increase included a $1.4 million increase in marketing and selling expenses associated with relaunching CytoGam and preparations to launch Respivir(TM), if and when approved for marketing by the United States Food and Drug Administration (FDA). Respivir(TM), MedImmune's second product, is currently under review by the FDA for marketing approval for prevention of respiratory syncytial virus (RSV) infection in certain high risk children.
 "The results for the second quarter were consistent with our objectives and reflect continued progress in the relaunch of CytoGam, preparations to launch Respivir, if and when approved for marketing by the FDA, and advancement of new products through the research and development pipeline," said Dr. Hockmeyer. "In addition, we believe the recently announced letter of intent with American Cyanamid Company to form a four product strategic alliance in the United States provides a major opportunity to enhance our market presence in the near term and our research pipeline in the long term. This letter of intent is subject to negotiation and execution of definitive agreements."
 MedImmune, Inc. was founded in 1988 to develop, manufacture and market therapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's corporate headquarters are in Gaithersburg.
 MEDIMMUNE, INC.
 Selected Financial Information
 Condensed Statements of Operations
 (In thousands, except per share data, unaudited)
 Periods ended Three months Six months
 June 30 1993 1992 1993 1992
 Revenues
 Product sales $1,853 $1,213 $3,406 $2,408
 Research and development 494 2,895 1,017 5,506
 Total 2,347 4,108 4,423 7,914
 Costs and expenses:
 Cost of sales 1,001 1,149 1,918 2,223
 Research and development 2,816 2,648 5,928 5,167
 Selling, administrative
 and general 2,245 785 4,424 1,506
 Total 6,062 4,582 12,270 8,896
 Interest income, net 397 645 909 1,273
 (Loss) earnings before taxes (3,318) 171 (6,938) 291
 Provision for income taxes 45 -- 90 25
 Net (loss) earnings (3,363) 171 (7,028) 266
 (Loss) earnings per share (0.20) 0.01 (0.42) 0.02
 Shares used in computing
 (loss) earnings per share 16,593 16,696 16,679 18,762
 CONDENSED BALANCE SHEETS
 6/30/93 12/31/92
 (unaudited)
 Assets:
 Cash and marketable securities $31,775 $46,860
 Inventory 4,140 4,048
 Property and equipment, net 7,496 6,114
 Other assets 4,786 3,221
 Total $48,197 $60,243
 Liabilities and shareholders' equity:
 Accounts payable and accrued expenses 2,021 1,513
 Obligations related to product acquisition 3,375 8,871
 Other liabilities 3,074 3,107
 Shareholders' equity 39,727 46,752
 Total $48,197 $60,243
 Common shares outstanding 13,431 13,386
 -0- 8/6/93
 /CONTACT: Emilio O. DiCataldo, senior vice president, Finance and Administration of MedImmune, Inc., 301-417-0770, or Anthony J. Russo, Ph.D. of Noonan/Russo Communications, Inc., 212-696-4455/
 (MEDI)


CO: MedImmune, Inc. ST: Maryland IN: MTC SU: ERN

LG-OS -- NY030 -- 0308 08/06/93 12:20 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 6, 1993
Words:717
Previous Article:GROW GROUP, INC. REPORTS YEAR-END RESULTS; GROW ATTAINS HIGH END OF FULL-YEAR FORECAST, 90 CENTS EPS, ON RECORD NET INCOME OF $12.5 MILLION
Next Article:INPUT/OUTPUT NAMES BROOK AND SHIELDS VICE PRESIDENTS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters